Volume 24, Number 1Prostate CancerUse of Radium-223 in Advanced Prostate CancerSoumyajit RoyAngela Y. JiaPedro C. BarataDaniel E. SprattRadium-223 dichloride (Ra-223) is a life-prolonging therapeutic option for castration-resistant prostate cancer with symptomatic bone metastases. As an α-emitting osteotropic radiopharmaceutical, Ra-223 selectively targets areas of increased bone turnover. Recent evidence from the PEACE III randomized trial demonstrated a radiographic progression-free survival and overall survival benefit with a combination of Ra-223 and enzalutamide, provided appropriate bone health measures are in place. There is also a growing body of evidence on the use of Ra-223 in metastatic hormone-sensitive prostate cancer. Robust phase 3 data, however, are needed to define its optimal integration into the current standard of care for these patients.Radioisotopesprostatic neoplasms, castration-resistantmetastatic hormone-sensitive prostate cancerProstatic neoplasms
Volume 24, Number 1Prostate CancerReal-World Outcomes for Patients With Metastatic Castration-Resistant Prostate Cancer Within a US Community Urology NetworkEmily N. SmythSam WhippleNicholas LazarouKatie GrantArpit KashyapZhanglin L. CuiNadine HaddadArjun V. BalarNeal D ShoreThe role of novel hormonal agents (NHAs) for advanced prostate cancer (PCa) has expanded over time to include treatment of metastatic and nonmetastatic disease. Additionally, in the last 5 years, select poly(ADP-ribose) polymerase (PARP) inhibitors have been FDA-approved and incorporated into treatment guidelines for homologous recombination repair and BRCA mutant metastatic castration-resistant prostate cancer (mCRPC). To understand the evolving treatment landscape and unmet medical needs in mCRPC, treatment patterns, patient characteristics, and outcomes within a large community urology network were evaluated.medical oncologyprostatic neoplasms, castration-resistantUrology